- Home
- STTK vs HGLB Comparison
STTK vs HGLB Comparison
Compare STTK & HGLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- HGLB
- Stock Information
- Founded
- STTK 2016
- HGLB 1998
- Country
- STTK United States
- HGLB United States
- Employees
- STTK N/A
- HGLB N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- HGLB Trusts Except Educational Religious and Charitable
- Sector
- STTK Health Care
- HGLB Finance
- Exchange
- STTK Nasdaq
- HGLB Nasdaq
- Market Cap
- STTK 173.6M
- HGLB 175.8M
- IPO Year
- STTK 2020
- HGLB N/A
- Fundamental
- Price
- STTK $3.68
- HGLB $7.76
- Analyst Decision
- STTK Strong Buy
- HGLB
- Analyst Count
- STTK 3
- HGLB 0
- Target Price
- STTK $10.67
- HGLB N/A
- AVG Volume (30 Days)
- STTK 152.9K
- HGLB 91.8K
- Earning Date
- STTK 11-07-2024
- HGLB 01-01-0001
- Dividend Yield
- STTK N/A
- HGLB 13.16%
- EPS Growth
- STTK N/A
- HGLB N/A
- EPS
- STTK N/A
- HGLB N/A
- Revenue
- STTK $4,123,999.00
- HGLB N/A
- Revenue This Year
- STTK $164.45
- HGLB N/A
- Revenue Next Year
- STTK N/A
- HGLB N/A
- P/E Ratio
- STTK N/A
- HGLB N/A
- Revenue Growth
- STTK 380.09
- HGLB N/A
- 52 Week Low
- STTK $1.33
- HGLB $6.42
- 52 Week High
- STTK $11.76
- HGLB $9.45
- Technical
- Relative Strength Index (RSI)
- STTK 49.66
- HGLB 56.49
- Support Level
- STTK $3.37
- HGLB $7.63
- Resistance Level
- STTK $3.75
- HGLB $7.85
- Average True Range (ATR)
- STTK 0.21
- HGLB 0.10
- MACD
- STTK 0.06
- HGLB 0.00
- Stochastic Oscillator
- STTK 66.67
- HGLB 89.09
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About HGLB Highland Global Allocation Fund
Highland Global Allocation Fund is a diversified, closed-end management investment company. The investment objective of the Fund is to seek long-term growth of capital and future income. The Fund seeks to achieve its investment objectives by investing in a portfolio of U.S. and foreign equity, debt, and money market securities. It may also invest in senior loans to domestic or foreign corporations, partnerships, and other entities that operate in a variety of industries and geographic regions.